Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates
Diagnostics · 19.11.2026 · 16 (22) · 3870
DOI: 10.3390/diagnostics16223870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 19.11.2026. Verfasst von Luis Alvarado und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Rapid molecular detection of carbapenemase-producing Gram-negative bacilli is crucial for targeted antimicrobial therapy, but regional gene sequence diversity can impair commercial PCR assays. This study evaluated the analytical inclusivity of three commercial real-time PCR platforms (Xpert Carba-R on the GeneXpert system, Galaxy Lite, and Molecular Mouse) against carbapenemase alleles circulating in Peru, including the regionally relevant blaIMP-74 and blaIMP-93 alleles.
Methods
We analyzed a positive-enriched challenge panel of 23 non-duplicate clinical isolates previously characterized by whole-genome sequencing (WGS): 10 Enterobacterales and 13 Pseudomonas aeruginosa carrying 26 carbapenemase genes across 12 variants (blaKPC-2/35, blaNDM-1/5, blaOXA-48/181/232, blaVIM-2, and blaIMP-16/18/74/93); inclusivity was calculated per WGS-confirmed target gene, and Molecular Mouse was evaluated on a 16-target subset including at least one representative of each allele.
Results
Galaxy Lite detected all carbapenemase alleles evaluated (12/12 alleles; gene-level analytical inclusivity 100%, 26/26 target genes, 95% CI: 86.8–100%). Xpert Carba-R and Molecular Mouse each detected 8 of the 12 alleles (100% of KPC, NDM, OXA-48-like, and VIM alleles), failing to detect any of the four IMP alleles evaluated. Overall gene-level inclusivity was 53.8% (14/26 target genes, 95% CI: 33.4–73.4%) for Xpert Carba-R and 62.5% (10/16 target genes, 95% CI: 35.4–84.8%) for Molecular Mouse.
Conclusions
In this small, positive-enriched panel, two of the three commercial PCR panels did not detect the IMP alleles tested, a finding that may be related to primer/probe–target sequence divergence, although this mechanism was not investigated. These results support the local verification of commercial carbapenemase PCR assays against circulating alleles before routine implementation.
Zitieren
APA
Alvarado, L., Quiroz-Reyna, M., Quiroz-Chunga, G., Castillo-Aguilar, W., & Pretell, J. C. G. D. L. T. (2026). Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates. Diagnostics, 16(22), 3870. https://doi.org/10.3390/diagnostics16223870
Vancouver
Alvarado L, Quiroz-Reyna M, Quiroz-Chunga G, Castillo-Aguilar W, Pretell JCGDLT. Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates. Diagnostics. 2026;16(22):3870. doi:10.3390/diagnostics16223870
BibTeX
@article{Alvarado2026,
author = {Alvarado, Luis and Quiroz-Reyna, Maritza and Quiroz-Chunga, Giancarlo and Castillo-Aguilar, William and Pretell, Juan Carlos Gomez de la Torre},
title = {Analytical Inclusivity of Three Commercial Real-Time PCR Platforms Against Carbapenemase Allelic Variants in Peruvian Clinical Isolates},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3870},
doi = {10.3390/diagnostics16223870}
}
EUVIMED